百利天恒：iza-bren用于铂耐药复发上皮性卵巢癌III期临床试验完成首例受试者入组

Core Viewpoint - The company, Baili Tianheng, has announced the completion of the first patient enrollment in a Phase III clinical trial for its first-in-class EGFR×HER3 dual-targeted antibody-drug conjugate (ADC), iza-bren, aimed at platinum-resistant recurrent epithelial ovarian cancer patients [1] Group 1 - The Phase III clinical trial for iza-bren is the only one of its kind that has entered this stage globally [1] - Currently, iza-bren is involved in over 40 clinical trials targeting various tumor types in both China and the United States [1] - In addition to the newly enrolled trial, iza-bren is also in the patient enrollment phase for nine domestic Phase III registration clinical trials, including those for non-small cell lung cancer, small cell lung cancer, breast cancer, nasopharyngeal carcinoma, esophageal squamous cell carcinoma, and urothelial carcinoma [1]